Previous 10 | Next 10 |
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmac...
2024-01-11 09:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 14:54:36 ET More on Markets Cathie Wood: Probability is very high that a Spot Bitcoin ETF will be approved this week Market returns are broadening out from the Magnificent 7 - Principal Financial Group Real Estate is the top performing sector since the mar...
2024-01-05 02:34:15 ET More on scPharmaceuticals scPharmaceuticals Q3 Earnings: Cruising Toward Success Seeking Alpha’s Quant Rating on scPharmaceuticals For further details see: scPharmaceuticals trades marginally higher on guiding revenue above consensus
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4 Inventory levels at the end of...
2023-12-25 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-12 02:57:45 ET Summary Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in its prospects. The company's healthy financia...
2023-11-08 21:58:05 ET scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript November 8, 2023 04:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Racha...
2023-11-08 16:03:20 ET More on scPharmaceuticals scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD Sizing Up scPharmaceuticals scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript scPharmaceuticals gains after regulatory u...
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments o f $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 ...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharma...
Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® revenue of $13.6 million, at the upper end of the range...
SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...